Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133356) titled 'A phase II study of trastuzumab Rezetecan and carboplatin with or without bevacizumab versus chemotherapy in patients with platinum-sensitive recurrent ovarian cancer' on Sept. 24.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Sun Yat-sen University Cancer Center (The Affiliated Tumor Hospital of Sun Yat-sen University, Sun Yat-sen University Cancer Institute)
Condition:
Platinum-sensitive recurrent epithelial ovarian cancer
Intervention:
Trial group:Ruikang Trastuzumab + Carboplatin +/- Bevacizumab: Ruikang Trastuzumab 4.0mg/kg, intravenous injection, once every 3 weeks (Q3W)
Car...